|
JPS5991308A
(ja)
*
|
1982-11-16 |
1984-05-26 |
Kawasaki Heavy Ind Ltd |
平面の検出方法
|
|
ES2245638T3
(es)
*
|
1999-01-27 |
2006-01-16 |
Becker, David, Dr. |
Formulaciones que comprenden nucleotidos antisentido para conexinas.
|
|
EP1197553A1
(en)
*
|
2000-10-12 |
2002-04-17 |
A3D GmbH, Antisense Design & Drug Development |
Antisense nucleic acid against alphaV integrin
|
|
US20050119211A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
|
|
CA2547780C
(en)
|
2003-12-03 |
2019-10-22 |
Coda Therapeutics (Nz) Ltd |
Antisense compounds targeted to connexins and methods of use thereof
|
|
US9408381B2
(en)
|
2004-12-21 |
2016-08-09 |
Musc Foundation For Research Development |
Alpha Connexin c-Terminal (ACT) peptides for use in transplant
|
|
JP5243040B2
(ja)
|
2004-12-21 |
2013-07-24 |
ムスク・ファウンデイション・フォー・リサーチ・ディベロップメント |
創傷治癒および組織再生を促進するための組成物および方法
|
|
JP5964538B2
(ja)
|
2005-02-03 |
2016-08-03 |
コーダ セラピューティクス， インコーポレイテッド |
抗コネキシン化合物およびそれらの使用
|
|
WO2007055224A1
(ja)
*
|
2005-11-08 |
2007-05-18 |
Kansai Technology Licensing Organization Co., Ltd. |
角膜疾患治療剤
|
|
EP1976567B1
(en)
|
2005-12-28 |
2020-05-13 |
The Scripps Research Institute |
Natural antisense and non-coding rna transcripts as drug targets
|
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のｓｉＲＮＡおよびその使用方法
|
|
EP2091557A2
(en)
*
|
2006-11-15 |
2009-08-26 |
Coda Therapeutics, INC. |
Improved methods and compositions for wound healing
|
|
AU2014204482B2
(en)
*
|
2006-12-11 |
2016-07-07 |
Coda Therapeutics, Inc. |
Anticonnexin polynucleotides as impaired wound healing compositions
|
|
EP2543377A1
(en)
*
|
2006-12-11 |
2013-01-09 |
Coda Therapeutics, INC. |
Anticonnexin polynucleotides as impaired wound healing compositions
|
|
DK2166845T3
(en)
*
|
2007-06-21 |
2016-02-01 |
Musc Found For Res Dev |
ALFA-connexin C-terminal (ACT) peptides FOR THE TREATMENT OF AGE-related macular degeneration
|
|
JP5646997B2
(ja)
|
2007-10-03 |
2014-12-24 |
クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
新規ｓｉＲＮＡ構造
|
|
CA2709151A1
(en)
|
2007-12-11 |
2009-06-18 |
Coda Therapeutics, Inc. |
Impaired wound healing compositions and treatments
|
|
CA2709153A1
(en)
*
|
2007-12-11 |
2009-06-18 |
Coda Therapeutics, Inc. |
Impaired wound healing compositions and treatments
|
|
AU2008343754A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Use of anti-connexin polynucleotides for the treatment of surgical adhesions
|
|
EP2237796A2
(en)
*
|
2007-12-21 |
2010-10-13 |
Coda Therapeutics, Inc. |
Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
|
|
US20110092449A1
(en)
*
|
2007-12-21 |
2011-04-21 |
Bradford James Duft |
Treatment of fibrotic conditions
|
|
CA2710382A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Treatment of orthopedic conditions
|
|
JP2011507862A
(ja)
*
|
2007-12-21 |
2011-03-10 |
コーダ セラピューティクス， インコーポレイテッド |
異常瘢痕または過剰瘢痕の治療のための抗コネキシン４３ポリヌクレオチドの使用
|
|
WO2009085274A2
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars
|
|
EP2237786A2
(en)
*
|
2007-12-21 |
2010-10-13 |
Coda Therapeutics, Inc. |
Use of inhibitors of connexin43 for treatment of fibrotic conditions
|
|
JP2011507856A
(ja)
*
|
2007-12-21 |
2011-03-10 |
コーダ セラピューティクス， インコーポレイテッド |
整形外科状態の治療のための抗コネキシンポリヌクレオチド、ペプチド、または抗体の使用
|
|
CA2710386A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Coda Therapeutics, Inc. |
Improved medical devices
|
|
US20110038920A1
(en)
*
|
2008-01-07 |
2011-02-17 |
Ryoichi Mori |
Wound healing compositions and treatments
|
|
EP3336188B1
(en)
|
2008-09-22 |
2020-05-06 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering rnai compounds
|
|
WO2010040112A2
(en)
|
2008-10-03 |
2010-04-08 |
Curna, Inc. |
Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
|
|
MX358603B
(es)
|
2008-12-04 |
2018-08-28 |
Curna Inc |
Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
|
|
EP2370581B1
(en)
|
2008-12-04 |
2016-08-03 |
CuRNA, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
|
RU2620970C2
(ru)
|
2008-12-04 |
2017-05-30 |
КьюРНА,Инк., |
Лечение связанных с эритропоэтином (еро) заболеваний путем ингибирования природного антисмыслового транскрипта к еро
|
|
US8669941B2
(en)
*
|
2009-01-05 |
2014-03-11 |
Nuance Communications, Inc. |
Method and apparatus for text entry
|
|
EP3009150B1
(en)
|
2009-02-12 |
2019-11-13 |
CuRNA, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
|
WO2010107733A2
(en)
|
2009-03-16 |
2010-09-23 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
|
ES2627763T3
(es)
|
2009-03-17 |
2017-07-31 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el homólogo tipo delta 1 (dlk1) por inhibición de transcrito antisentido natural a dlk1
|
|
US9155754B2
(en)
|
2009-05-06 |
2015-10-13 |
Curna, Inc. |
Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
|
|
EP2427552B1
(en)
|
2009-05-06 |
2016-11-16 |
CuRNA, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
|
CA2761248C
(en)
|
2009-05-08 |
2023-03-14 |
Joseph Collard |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
|
DK2432881T3
(en)
|
2009-05-18 |
2018-02-26 |
Curna Inc |
TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
|
|
WO2010135695A2
(en)
|
2009-05-22 |
2010-11-25 |
Curna, Inc. |
TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
|
|
ES2618576T3
(es)
|
2009-05-28 |
2017-06-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen antivírico mediante la inhibición de una transcripción antisentido natural a un gen antivírico
|
|
KR101801404B1
(ko)
|
2009-06-16 |
2017-12-20 |
큐알엔에이, 인크. |
콜라겐 유전자에 대한 천연 안티센스 전사체의 억제에 의한 콜라겐 유전자 관련된 질환의 치료
|
|
KR101702689B1
(ko)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Ｐｏｎ1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(ｐｏｎ1) 관련된 질환의 치료
|
|
JP6073133B2
(ja)
|
2009-06-24 |
2017-02-01 |
クルナ・インコーポレーテッド |
腫瘍壊死因子受容体２（ｔｎｆｒ２）に対する天然アンチセンス転写物の抑制によるｔｎｆｒ２関連疾患の治療
|
|
ES2583691T3
(es)
|
2009-06-26 |
2016-09-21 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen del síndrome de Down mediante la inhibición de una transcripción antisentido natural a un gen del síndrome de Down
|
|
US20120252869A1
(en)
|
2009-07-24 |
2012-10-04 |
Opko Curna, Llc |
Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
|
|
KR101802536B1
(ko)
|
2009-08-05 |
2017-11-28 |
큐알엔에이, 인크. |
인슐린 유전자 (ｉｎｓ)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ｉｎｓ) 관련된 질환의 치료
|
|
WO2011019815A2
(en)
|
2009-08-11 |
2011-02-17 |
Curna, Inc. |
Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
|
|
CN102482670B
(zh)
|
2009-08-21 |
2018-06-15 |
库尔纳公司 |
通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
|
|
CA2771172C
(en)
|
2009-08-25 |
2021-11-30 |
Opko Curna, Llc |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
|
ES2664591T3
(es)
|
2009-09-25 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la filagrina (flg) mediante la modulación de la expresión y actividad del gen FLG
|
|
NO2513310T3
(cg-RX-API-DMAC10.html)
|
2009-12-16 |
2018-03-31 |
|
|
|
EP2515947B1
(en)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
|
JP5934106B2
(ja)
|
2009-12-23 |
2016-06-15 |
カッパーアールエヌエー，インコーポレイテッド |
肝細胞増殖因子（ｈｇｆ）に対する天然アンチセンス転写物の阻害によるｈｇｆ関連性疾患の治療
|
|
JP5993744B2
(ja)
|
2009-12-29 |
2016-09-14 |
カッパーアールエヌエー，インコーポレイテッド |
核呼吸因子１（ｎｒｆ１）に対する天然アンチセンス転写物の阻害による核呼吸因子１関連疾患の治療
|
|
EP2519634B1
(en)
|
2009-12-29 |
2016-06-01 |
CuRNA, Inc. |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
|
US20120289583A1
(en)
|
2009-12-31 |
2012-11-15 |
Curna, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
|
NO2521784T3
(cg-RX-API-DMAC10.html)
|
2010-01-04 |
2018-05-05 |
|
|
|
CA2786056C
(en)
|
2010-01-06 |
2023-03-14 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
|
EP2524039B1
(en)
|
2010-01-11 |
2017-11-29 |
CuRNA, Inc. |
Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg
|
|
WO2011091390A2
(en)
|
2010-01-25 |
2011-07-28 |
Opko Curna, Llc |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
|
WO2011103528A2
(en)
|
2010-02-22 |
2011-08-25 |
Opko Curna Llc |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
|
KR101852210B1
(ko)
|
2010-03-24 |
2018-04-25 |
알엑스아이 파마슈티칼스 코포레이션 |
진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
|
|
EP2553098B1
(en)
|
2010-04-02 |
2017-10-11 |
CuRNA, Inc. |
Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
|
|
RU2610661C2
(ru)
|
2010-04-09 |
2017-02-14 |
Курна, Инк. |
Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
|
|
KR101915115B1
(ko)
|
2010-05-03 |
2018-11-05 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
|
|
DK2576783T3
(en)
|
2010-05-26 |
2018-03-12 |
Curna Inc |
TREATMENT OF ATONAL HOMOLOGY 1- (ATOH1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS AT ATOH1
|
|
ES2664585T3
(es)
|
2010-05-26 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con metionina sulfóxido reductasa (MSRA) mediante inhibición del transcrito antisentido natural a MSRA
|
|
JP6023705B2
(ja)
|
2010-06-23 |
2016-11-09 |
カッパーアールエヌエー，インコーポレイテッド |
ナトリウムチャネル、電位依存性、αサブユニット（ＳＣＮＡ）に対する天然アンチセンス転写物の阻害によるＳＣＮＡ関連疾患の治療
|
|
CN103068982B
(zh)
|
2010-07-14 |
2017-06-09 |
库尔纳公司 |
通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
|
|
JP5986998B2
(ja)
|
2010-10-06 |
2016-09-06 |
カッパーアールエヌエー，インコーポレイテッド |
シアリダーゼ４（ｎｅｕ４）への天然アンチセンス転写物の阻害によるｎｅｕ４関連疾患の治療
|
|
WO2012054723A2
(en)
|
2010-10-22 |
2012-04-26 |
Opko Curna Llc |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
|
ES2657590T3
(es)
|
2010-11-23 |
2018-03-06 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con nanog mediante inhibición del transcrito antisentido natural a nanog
|
|
EP2718439B1
(en)
|
2011-06-09 |
2017-08-09 |
CuRNA, Inc. |
Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn
|
|
KR101991980B1
(ko)
|
2011-09-06 |
2019-06-21 |
큐알엔에이, 인크. |
소형 분자로 전압-개폐된 나트륨 채널 (SCNxA)의 알파 아단위에 관련된 질환의 치료
|
|
CA2864606C
(en)
|
2012-02-15 |
2021-06-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of treating and preventing diseases and disorders of the central nervous system
|
|
CA2866115C
(en)
|
2012-03-01 |
2020-03-24 |
Firststring Research, Inc. |
Topical gels containing alpha connexin c-terminal (act) peptides
|
|
CN110438125A
(zh)
|
2012-03-15 |
2019-11-12 |
科纳公司 |
通过抑制脑源神经营养因子(bdnf)的天然反义转录物治疗bdnf相关疾病
|
|
US20140274872A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Coda Therapeutics, Inc. |
Compositions and treatments based on cadherin modulation
|
|
JP2015513905A
(ja)
|
2012-03-27 |
2015-05-18 |
コーダ セラピューティクス， インコーポレイテッド |
カドヘリン調節に基づく組成物および処置
|
|
WO2014164805A1
(en)
*
|
2013-03-11 |
2014-10-09 |
University Of North Carolina At Chapel Hill |
Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
|
|
US9156896B2
(en)
|
2013-03-15 |
2015-10-13 |
Coda Therapeutics, Inc. |
Wound healing compositions and treatments
|
|
JP6883987B2
(ja)
*
|
2013-12-04 |
2021-06-09 |
フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． |
化学修飾されたオリゴヌクレオチドを利用する創傷治癒の処置のための方法
|
|
CA2940648A1
(en)
*
|
2014-02-25 |
2015-09-03 |
Coda Therapeutics, Inc. |
Treatment of resistant lesions
|
|
US20170106047A1
(en)
|
2014-06-12 |
2017-04-20 |
The Research Foundation For The State University Of New York |
Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina
|
|
CN114010788A
(zh)
|
2014-08-22 |
2022-02-08 |
奥克兰联合服务有限公司 |
通道调节剂
|
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
|
CA3015839A1
(en)
*
|
2016-02-26 |
2017-08-31 |
The Board Of Regents Of The University Of Texas System |
Connexin (cx)43 hemichannel-binding antibodies and uses thereof
|
|
CN111201247A
(zh)
|
2017-04-28 |
2020-05-26 |
奥克兰联合服务有限公司 |
治疗方法和新颖构建体
|
|
EP3685824A1
(en)
*
|
2019-01-25 |
2020-07-29 |
Breitenbronn-Consulting GbR |
Composition for administering and releasing oligonucleotides
|
|
JP2023546757A
(ja)
|
2020-10-22 |
2023-11-07 |
シークエル・バイオ・インコーポレイテッド |
ペプチド製剤および眼科におけるその使用
|
|
US20250289864A1
(en)
*
|
2022-05-13 |
2025-09-18 |
University Of Utah Research Foundation |
Gja1-20k to limited cardiac arrhythmias
|